期刊文献+

卡培他滨联合奥曲肽对人乳腺癌细胞MCF-7增殖的影响 被引量:4

Effects of capecitabine combined with octreotide on proliferation of human breast cancer cell MCF-7
原文传递
导出
摘要 目的 观察卡培他滨联合奥曲肽对乳腺癌MCF-7细胞增殖周期的影响.方法 实验分为4组:对照组、卡培他滨组、奥曲肽组、联合组(卡培他滨+奥曲肽).每组分为不同浓度,以MTT法检测细胞增殖状况.结果 卡培他滨与奥曲肽在较高浓度水平联用抑制MCF-7细胞增殖,MCF细胞生长初期(4d内)生长速度较快,滞后逐渐减慢,9d后细胞生长趋于停滞;在高浓度水平联用抑制MCF-7细胞生长,表现为协同作用.结论 卡培他滨联合奥曲肽对MCF-7细胞增殖具有抑制作用. Objective To study the effect of capecitabine combined with octreotide on proliferation cycle of breast cancer MCF-7 cells.Methods The experiments were divided into 4 groups:control group,capecitabine group,octreotide group,combined group (capecitabine plus octreotide),and subgroups of each group were set up according to the concentrations.Cell proliferation was measured by methyl thiazol tetrazolium (MTT) assay.Results Combined use of capecitaine and octreotide in high concentrations could inhibited the proliferation of MCF-7 cells.The MCF cells grew faster within 4 days,then gradually slowed down,and 9 days later cell growth tended to stagnate.Capecitaine and octreotide in high concentrations showed a synergistic effect.Conclusion Capecitabine combined with octreotide can inhibit the proliferation of MCF-7 cells.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2015年第5期996-997,共2页 Chinese Journal of Experimental Surgery
关键词 卡培他滨 奥曲肽 乳腺癌 增殖 Capecitabine Octreotide Breast cancer Proliferation
  • 相关文献

参考文献9

二级参考文献50

  • 1曾希志,姚榛祥.三苯氧胺阻断外源性雌激素致乳癌的实验研究[J].中华外科杂志,1996,34(3):176-179. 被引量:10
  • 2蔡伟,康骅.介绍一种乳腺癌术后局部少量皮下积液的简易负压引流法[J].中国实用外科杂志,2006,26(11):876-876. 被引量:8
  • 3Tsao MS, Liu G, Shepherd FA. Serum proteornic classifier for predicting response to epidermal growth factor receptor inhibitor therapy: have we built a better mousetrap? J Nail Cancer Inst, 2007, 99(11): 826-827.
  • 4Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics, 2007, 4(1): 51-65.
  • 5Diamandis EP. Serum proteomic profiling by matrix-assisted laser desorption- ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res, 2006, 66(11): 5540-5541.
  • 6Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spec- trometry. Clin Chem, 2007, 53(5): 852-858.
  • 7Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008, 372(9652): 1809-1818.
  • 8Kima HS, Parka K, Juna HJ, et al. Comparison ofsurviva/in advanced nonsmall cell lung cancer patients in the pre- and post-gefifinib eras. Oncology, 2009, 76(4): 239-246.
  • 9Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N EnglJ Med, 2005, 352(8): 786-792.
  • 10Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non- small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort crossinstitutional study. J Nail Cancer Inst, 2007, 99(11): 838-846.

共引文献22

同被引文献42

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部